Eli Lilly Pledges to Bring GLP-1s to Lower-Income Countries
The new Lilly Change the Course Commitment aims to treat as many people with diabetes and obesity in low- and middle-income countries as in wealthy ones by 2040.
Two New FDA-Approved Treatments Give People With FOP More Options
In five weeks, the FDA approved Regeneron's Pasatru and Mirum's Atebrioz for fibrodysplasia ossificans progressiva, a rare disease that slowly turns muscle and tendons into bone.
Trump Orders a Smaller-Dose Childhood Vaccine Schedule — Here's What Actually Changed
A White House executive order is reshaping how many diseases U.S. children are routinely vaccinated against, and how their shots are delivered. Pediatric and vaccine experts say the reasoning behind it doesn't hold up — and warn the changes could mean more visits, not safer ones.
Montana's Right-to-Try Experiment
A new state law lets biotech companies sell drugs that have cleared only the smallest, earliest phase of testing — no FDA approval required. Supporters call it a lifeline for patients out of options. Critics call it a $12,500-application-fee shortcut around the system that keeps medicine safe.
Novo Nordisk's Oral Semaglutide Hits the Mark in Landmark Pediatric Diabetes Trial
The PIONEER TEENS Phase 3 trial delivered statistically significant blood sugar improvements in children as young as 10 — and could bring the first pill-based GLP-1 therapy to young people with type 2 diabetes.
Louisiana's Abortion Pill Case Could Wipe Out Access in Blue States
Louisiana will argue before a federal appeals court that FDA rules allowing telehealth prescription and mail delivery of mifepristone infringe on its right to prohibit abortion — but if it succeeds, it would wipe out online and mail access in states where abortion is legal, cutting off millions from a method they increasingly depend on.